Personalised cancer medicine

International Journal of Cancer

Volumn 137, Issue 2, 2015, Pages 262-266

  Jackson, Sarah E ^a   Chester, John D ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

cancer predisposition genes; monoclonal antibody; PARP inhibitor; stratified medicine; synthetic lethality; tyrosine kinase inhibitor

Indexed keywords

4 AMINO N [1 (4 CHLOROPHENYL) 3 HYDROXYPROPYL] 1 (7H PYRROLO[2,3 D]PYRIMIDIN 4 YL) 4 PIPERIDINECARBOXAMIDE; ACETYLSALICYLIC ACID; CETUXIMAB; CRIZOTINIB; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; OLAPARIB; PACLITAXEL; RALOXIFENE; TRASTUZUMAB; VEMURAFENIB;

ADVANCED CANCER; BLADDER CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER SUSCEPTIBILITY; CHEMOPROPHYLAXIS; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; COLORECTAL CANCER; DISEASE SEVERITY; DRUG EFFICACY; DRUG SELECTIVITY; DRUG SENSITIVITY; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; INTRACELLULAR SIGNALING; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; NON SMALL CELL LUNG CANCER; OVARY CANCER; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; GENETIC PREDISPOSITION; GENETICS; NEOPLASMS; ONCOLOGY; PROCEDURES; PROGNOSIS; RISK FACTOR; TRENDS;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIVIDUALIZED MEDICINE; MEDICAL ONCOLOGY; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROGNOSIS; RISK FACTORS;

EID: 84929243899     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28940     Document Type: Review

References (45)

1. Zhou Z,. Clinical pharmacogenomics of thiopurine S-methyltransferase. Curr Clin Pharmacol 2006; 1: 119-28.
2. Wilson JMG, Jungner G,. Principles and practice of screening for disease. World Health Organization Public Health Papers No. 34, 1968.
3. Martino S, Costantino J, McNabb M, et al. The role of selective oestrogen receptor modulators in the prevention of breast cancer: comparison of the trials. Oncologist 2004; 9: 116-25.
4. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA 2006; 295: 2727-41.
5. Rhaman N, Stratton MR,. The genetics of breast cancer susceptibility. Annu Rev Genet 1998; 32: 95-121.
6. Chen S, Parmigiani G,. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007; 25: 1329-33.
7. Lostumbo L, Carbine NE, Wallace J,. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev 2010; 11: CD002748.
8. Singh K, Lester J, Karlan B, et al. Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers. Am J Obstet Gynecol 2013; 208: 329.e1-6.
9. Pineda M, González S, Lázaro C, et al. Detection of genetic alterations in hereditary colorectal cancer screening. Mutat Res 2010; 693: 19-31.
10. Half E, Bercovich D, Rozen P,. Familial adenomatous polyposis. Orphanet J Rare Dis 2009; 4: 22.
11. Kartheuser A, Stangherlin P, Brandt D, et al. Restorative proctocolectomy and ileal pouch-anal anastomosis for familial adenomatous polyposis revisited. Fam Cancer 2006; 5: 241-60; discussion 261-2.
12. Galiatsatos P, Foulkes WD,. Familial adenomatous polyposis. Nature 2006; 101: 385-98.
13. Rothwell PM, Wilson M, Price JF, et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012; 379: 1591-601.
14. Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011; 378: 2081-7.
15. Arber N, Levin B,. Chemoprevention of colorectal neoplasia: the potential for personalized medicine. Gastroenterology 2008; 134: 1224-37.
16. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-65.
17. Fearon ER,. Molecular genetics of colorectal cancer. Annu Rev Pathol 2011; 6: 479-507.
18. European Medicines Agency. Committee for Medicinal Products for Human Use Post-Authorisation Summary of Positive Opinion for Erbitux. Doc.Ref. EMEA/CHMP/280402/2008. London 2008. Available at: http://www.emea.europa.eu/docs/en-GB/document-library/Summary-of-opinion/human/000558/WC500059827.pdf.
19. Goldenberg MM,. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999; 21: 309-18.
20. Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 2012; 4: CD006243.
21. Smith BD,. Imatinib for chronic myeloid leukemia: the impact of its effectiveness and long-term side effects. J Natl Cancer Inst 2011; 103: 527-9.
22. Goldman JM, Marin D,. Is imatinib still and acceptable first-line treatment for CML in chronic phase? Oncology 2012; 26: 901-7.
23. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342-9.
24. Hornick JL, Fletcher CDM,. The role of KIT in the management of patients with gastrointestinal stromal tumors. Hum Pathol 2007; 38: 679-87.
25. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-8.
26. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-32.
27. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-46.
28. Wang Y, Schmid-Bindert G, Zhou C,. Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians. Ther Adv Med Oncol 2012; 4: 19-29.
29. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27: 4247-53.
30. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368: 2385-94.
31. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
32. Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 2008; 105: 3041-6.
33. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-34.
34. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011; 12: 852-61.
35. Wheeler DL, Dunn EF, Harari PM,. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 2010; 7: 493-507.
36. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-7.
37. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-57.
38. Kaelin WG,. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005; 5: 689-98.
39. Nijman SMB,. Synthetic lethality: general principles, utility and detection using genetic screens in human cells. FEBS Lett 2011; 585: 1-6.
40. Shaw E, Tuff A, Sharpe R, et al. Emerging findings in the Cancer Research UK Stratified Medicine Programme. J Clin Oncol 2012;(Suppl): abstr TPS10633.
41. Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011; 1: 44-53.
42. ClinicalTrials.gov. Investigating safety, tolerability and efficacy of AZD5363 when combined with paclitaxel in breast cancer patients (BEECH). Available at: http://clinicaltrials.gov/show/NCT01625286.
43. ClinicalTrials.gov. A double blind randomised study of lapatinib and placebo in metastatic TCC of the urothelium (LaMB). Available at: http://clinicaltrials.gov/show/NCT00949455.
44. Pao W, Chmielecki J,. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010; 10: 760-74.
45. Sullivan RJ, Flaherty KT,. Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer 2013; 49: 1297-304.